Drug intelligence / Profile preview

EPI-422

Development stage: Preclinical
Lead developer: EpiBiologics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

EPI-422 is a monoclonal antibody (mAb) being developed by EpiBiologics for the treatment of autoimmune diseases. The antibody is engineered to target both soluble and membrane-bound forms of an undisclosed biological target, a strategy intended to enhance therapeutic efficacy in immune-mediated conditions. As of 2024, the program is in the IND-enabling phase, progressing toward clinical trials.

Beyond the preview

Go deeper on EPI-422.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EPI-422.

Explore the full profile